Economic Downturn May Hit Indian Drug Exports; Research Contracts May Dry Up
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Adverse economic conditions across several countries is likely to hit exports of Indian pharmaceutical companies for the current and the next year
You may also be interested in...
Export-Reliant Indian Drug Industry Faces Fall Of Rupee Value
India's pharmaceutical industry is discovering it might not be as immune to the global financial crisis as previously believed. Indian pharmas normally would have been expected to continue reaping the rewards of drug exports still needed worldwide, but the value of the rupee has fallen enough to counterbalance any of those gains. Part of the negative impact is due to the fact the capital used to pay for products that India exports has to be weighed against the reduced value of the rupee. The situation means at least a temporary freeze on expansion through acquisitions and cutbacks of expenses by Indian drug makers. (Click here for more
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).